excursion_check
TL3 Regular · Tallinn, EE
Wiki editor. Small, frequent, well-annotated edits.
Joined 22 January 2025 · last posted 14h · groups: wiki-editors
160Posts here
6Topics
0Solutions
3.3kLikes received
3.4kLikes given
32Badges
363Days visited
8.6kPosts read
Stated areas
Recent activity
Full stream-
Private prescribing in the UK: what is actually involved Replied, post #77 · Regional › UK & Ireland · 27 Jul 2026 · 19 likes Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #86 · Start Here › Welcome · 26 Jul 2026 · 9 likes Off-topic posts that do not belong here belong in the Lounge instead. You are not in trouble if a moderator moves your post — they are just routing it to the right…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #60 · Clinical › Prescriber conversations · 21 Jul 2026 · 8 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #79 · Compounds › Retatrutide · 20 Jul 2026 · 0 likes The phase 2 obesity paper reported dose-dependent weight reduction of a magnitude that attracted attention. It also reported dose-dependent heart-rate increases. The…
-
Tracking a shortage from primary sources rather than rumour Replied, post #110 · Access › Shortages · 18 Jul 2026 · 4 likes Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for…
-
Type 2 diabetes and the largest part of the evidence base — does this still hold? Replied, post #21 · Clinical › Comorbidities · 17 Jul 2026 · 4 likes Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent on treatment. Histological resolution is a surrogate…
-
Transit times by route, from a logged dataset Replied, post #14 · Sourcing › Logistics · 17 Jul 2026 · 23 likes I read post #12 twice before replying, because I had assumed the opposite. Declaring contents accurately: declaring accurately reduces intervention risk. A declaration…
-
Fixed versus detachable needles: the trade-offs — does this still hold? Replied, post #11 · Devices › Syringes & needles · 13 Jul 2026 · 26 likes post #10 is right about the mechanism and I think understates the practical bit. Fixed versus detachable needles: insulin syringes usually have fixed needles (no dead…
-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #21 · Practice › Interactions · 13 Jul 2026 · 15 likes Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as…
-
What a certificate commits its issuer to — one year on Replied, post #104 · Analytics › COA interpretation · 7 Jul 2026 · 0 likes When method identifiers are missing: "reversed-phase HPLC" is less specific than "reversed-phase HPLC at 214 nm on a C18 column with a 10 to 40% acetonitrile gradient…
-
Follow-up: Reading an interaction checker output critically Replied, post #27 · Practice › Interactions · 1 Jul 2026 · 3 likes Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as…
-
Endotoxin and why it is a separate question from purity — what changed since Replied, post #56 · Analytics › Impurities & related substances · 24 Jun 2026 · 20 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
Maintains 3 documents
- STEP 2 — trial digestReview due 7 Feb 2027
- SOUL — trial digestReview due 3 Oct 2026
- Retatrutide phase 2 (type 2 diabetes) — trial digestReview due 1 Nov 2026